During high-speed rotary compaction of sulfadimidine base intended for 500 mg veterinary tablets, the as-supplied crystals frequently exhibit bulk densities between 0.38 g/mL and 0.45 g/mL and Hausner ratios above 1.35, conditions that oppose direct compression on rotary presses operating above 40 rpm. Weight variation drifts outside Ph. Eur. 2.9.5 limits within the first 15 minutes of an uninterrupted direct compression run because die fill becomes erratic under forced feeder speeds above 30 rpm. The preferred route is aqueous wet granulation in a high-shear mixer with a load factor of 0.55–0.65, using povidone K30 at 2.5–4.0% w/w as binder and purified water at 20–25% w/w as granulation fluid. End-point detection by impeller torque rise of 8–12% over the dry mix baseline reduces over-wetting, which is the principal cause of tablet capping at compression forces above 15 kN. Granules are dried in a fluid-bed dryer at an inlet air temperature not exceeding 60°C until loss on drying is 1.5–2.5% w/w, then screened through a 1.0 mm sieve. Extra-granular sodium starch glycolate at 4.0% w/w and magnesium stearate at 0.75% w/w are blended into the dried granules for 5 minutes in a bin blender at 60% vessel fill volume. Lubrication beyond 8 minutes produces a hydrophobic film on granule surfaces and slows dissolution below compendial acceptance. Tablets are compressed on a 16-station rotary press to hardness 50–80 N and friability below 0.5% after 100 revolutions in a friabilator operated per Ph. Eur. 2.9.7. Release testing includes disintegration in water at 37 ± 2°C with complete disintegration inside 15 minutes and dissolution testing under Ph. Eur. 2.9.3 using 0.1 M HCl at 900 mL and paddle speed 50 rpm. The terminal dosage form is an uncoated or film-coated tablet supplied in light-resistant blister packs because sulfadimidine discolours on prolonged exposure to UV light. Aqueous granulation avoids residual solvent limits under ICH Q3C, but drying below 1.0% w/w moisture renders granules brittle and increases fines that segregate during compression.

What Limits Terminal Sterilization Windows for Sulfadimidine Sodium Injection Concentrates?

Sulfadimidine sodium injection concentrates are manufactured at 200 mg/mL or 333 mg/mL by dissolving the sodium salt in Water for Injections that has been nitrogen-sparged to a dissolved oxygen level below 0.5 mg/L. The solution is adjusted to pH 9.5–10.5 with sodium hydroxide or hydrochloric acid and filtered through a 0.2 µm polyethersulfone cartridge before filling into amber Type I glass vials or ampoules. Terminal steam sterilisation at 121°C for 15 minutes is applied only after the formulation has been shown to be free of reducing sugars. Dextrose-containing vehicles are avoided because Maillard degradation involving the aromatic amine at pH above 9.0 produces yellow-brown discolouration within 24 hours at 25°C. Porous-load autoclave cycles for batch volumes above 200 L may exhibit temperature equilibration lag exceeding 8 minutes in 100 mL vials, requiring cycle hold time extension based on thermocouple penetration studies in the largest container volume. Sodium metabisulfite at 0.1% w/v is sometimes included as an oxygen scavenger, but its use in parenteral products is restricted in certain markets where sulfite sensitivity is documented. If the injection is diluted in 0.9% sodium chloride or 5% dextrose so that the final pH falls below 8.5, free sulfadimidine base precipitates as needle-like crystals that cannot be redissolved without heating. This precipitation is a known transfusion-line incompatibility when polyionic intravenous fluids are co-administered. Release testing includes sterility per Ph. Eur. 2.6.1, bacterial endotoxins per Ph. Eur. 2.6.14, visible particulates per Ph. Eur. 2.9.20, sub-visible particulates per Ph. Eur. 2.9.19, and extractable volume per Ph. Eur. 2.9.17. The terminally sterilised vials are stored below 25°C; accelerated stability at 40°C/75% RH for 6 months typically shows pH drift not exceeding 0.3 units in nitrogen-blanketed formulations. Without nitrogen blanketing, ampoule headspace oxygen causes assay loss of 1.5–3.0% over 12 months at 25°C/60% RH.

Where sulfadimidine sodium is supplied as a water-soluble powder for mass medication in drinking-water systems, the principal process risk is segregation of fine API from a coarse carrier during pneumatic transfer into 25 kg foil-lined bags. The sodium salt has aqueous solubility approximately 100 g/L at 20°C, but its hygroscopicity can raise moisture uptake to 3.5–5.0% at 60% RH, leading to clumping and incomplete dissolution in hard water containing 500 mg/L calcium carbonate equivalents. Anhydrous glucose or maltodextrin is selected as carrier instead of lactose to reduce Maillard degradation risk. The API is milled to a particle size D90 below 100 µm before blending in a ribbon mixer at 80–90% fill volume and 25 rpm for 10–12 minutes, with the intensifier bar run for the first 3 minutes to break soft agglomerates. Discharged powder is screened through a 1.0 mm stainless-steel sieve and filled into aluminium-foil bags with desiccant. Blend uniformity is verified per Ph. Eur. 2.9.6 by sampling 10 locations in the blender, with acceptance of 90.0–110.0% label claim and relative standard deviation below 5.0%. Dissolution testing of the powder in simulated drinking water at 200 mg/L and 15–20°C should show complete dissolution within 5 minutes without floating particles or sediment. The finished powder is reconstituted at 100–250 mg sulfadimidine sodium per litre under veterinary prescription for short-duration mass medication. In automated proportioning pumps, the solubility limit imposes a maximum stock solution concentration above which the sodium salt forms a saturated layer at the bottom of the tank; stock solutions greater than 10% w/v are not recommended for continuous dosing systems. Hard water above 300 mg/L CaCO₃ may require a chelating agent, but citrate or EDTA additions above 0.2% can alter palatability and should be avoided unless validated for the target species.

When Sulfadimidine Premixes Enter Pelleted Feed After Steam Conditioning

In medicated feed operations, sulfadimidine premixes are produced at 20% w/w or 25% w/w active substance on a calcium carbonate or wheat bran carrier. The API is milled to D90 below 100 µm before layering onto the carrier in a horizontal paddle mixer. Premix is incorporated into complete feed at 2–4 kg/tonne to yield 100–200 mg/kg final feed. During steam conditioning at 75–80°C with retention time 30–60 seconds, sulfadimidine sodium remains chemically detectable by HPLC with losses typically below 7%, but published data for this specific configuration is limited and recovery should be confirmed by feed-mill trial sampling. Hot pelleting above 85°C or prolonged conditioning beyond 120 seconds can increase degradation and should be avoided unless stability data support the specific mash formulation. Organic acid preservatives such as propionic acid or formic acid above 0.5% in the feed can lower local pH, reduce extraction recovery of the sulfonamide, and should be segregated in the mixer or added after pelleting. Cross-contamination control requires a flush sequence with ground maize after every medicated lot; subsequent non-medicated feed must contain less than 10 ppm sulfadimidine residue by HPLC. The final pelleted feed is tested for homogeneity by riffle sampling of 10 samples, with acceptance of 90–110% label claim and coefficient of variation below 10%. Equipment that processes sulfadimidine premix should be dedicated or fitted with clean-in-place procedures because the sulfonamide adheres to electrostatic surfaces under low humidity conditions below 30% RH. Bulk fill systems using vacuum transfer generate static charge that can stratify the premix; granulated carriers with density within 0.45–0.60 g/mL of the milled API reduce this effect.

Low-Dose Capsule Filling for Companion Animal Formularies

On semi-automatic capsule filling lines, sulfadimidine capsules for companion animals are produced in size 3 or size 4 hard gelatin capsules containing 100 mg of micronised API. The API is pre-milled to D90 below 75 µm because larger crystals create content uniformity failures under Ph. Eur. 2.9.6 and slow dissolution in gastric-fluid simulation. The dry blend consists of lactose monohydrate or microcrystalline cellulose as filler, colloidal silicon dioxide at 0.5–1.0% w/w as glidant, and sodium starch glycolate at 4.0% w/w as disintegrant. Magnesium stearate at 0.5% w/w is added last and blended for 3–5 minutes; longer lubrication collapses the dissolution profile. Encapsulation is performed at 35–45% RH and 18–22°C because gelatin capsules become brittle below 35% RH and sticky above 45% RH. Fill weight variation is controlled to ±5% for individual capsules and average weight within ±3% of target. Release testing includes disintegration in 0.1 M HCl at 37 ± 2°C with complete disintegration inside 15 minutes and dissolution under USP 711 apparatus II at 50 rpm. Capsule shells may be preserved with methylparaben and propylparaben when non-gelatin hydroxypropyl methylcellulose shells are used for preservative-free fills. Hygroscopic formulations containing more than 3% moisture after encapsulation should not be packed in polyvinyl chloride blisters without desiccant because capsule softening and cross-linking accelerate above 40°C during distribution.

Terminal Filtration and Nitrogen Blanketing of Multi-Dose Oral Drench Formulations

Sulfadimidine sodium oral drench solutions at 200 mg/mL are prepared in stainless-steel compounding vessels with demineralised water and buffered to pH 9.5 using trisodium phosphate or sodium hydroxide. Typical preservative concentrations are methyl parahydroxybenzoate 0.18% w/v and propyl parahydroxybenzoate 0.02% w/v; product pH above 9.0 reduces but does not eliminate parabens’ antimicrobial activity, so preservative efficacy is verified by Ph. Eur. 5.1.3. The solution is filtered through a 0.2 µm polyethersulfone cartridge and filled into high-density polyethylene or amber glass bottles flushed with pharmaceutical-grade nitrogen. Multi-dose containers are stored below 25°C and protected from light; under accelerated conditions of 40°C/75% RH for 6 months, pH drift should not exceed 0.3 units and assay loss should remain under 3.0%. Without nitrogen blanketing, dissolved oxygen induces slow formation of coloured oxidation products that lower assay and shift the UV spectrum. In-use stability after first opening should be assessed by simulated withdrawal of 10 mL daily for 14 days; solution exposed to repeated air ingress may form white surface crusts at the cap if the pH falls below 8.5. The finished oral drench is administered through plastic dosing guns calibrated to 5 g or 10 g; viscosity of 1.5–3.0 mPa·s at 20°C allows consistent flow through silicone-rubber nozzles. Terminal filtration before filling is preferred over heat treatment because prolonged heating above 80°C without pH buffering accelerates sulfonamide hydrolysis and liberates free aromatic amine degradation products, which are monitored by related-substances HPLC at UV detection 254 nm.

Dosage form	Critical test	Standard or method	Typical specification
Tablets	Uniformity of content	Ph. Eur. 2.9.6	90.0–110.0% label claim, RSD ≤5.0%
Tablets	Dissolution	Ph. Eur. 2.9.3, USP 711	Not less than 75% in 45 min, 0.1 M HCl, paddle 50 rpm
Injections	Sterility	Ph. Eur. 2.6.1	Sterile
Injections	Bacterial endotoxins	Ph. Eur. 2.6.14	Less than 0.50 EU/mg of sulfadimidine sodium
Oral powders	Blend uniformity	Ph. Eur. 2.9.6	90.0–110.0% label claim, RSD ≤5.0%
Feed premix	Homogeneity in feed	In-house HPLC	90–110% label claim, CV ≤10%
Capsules	Disintegration	Ph. Eur. 2.9.1	Complete in 15 min, 0.1 M HCl, 37 ± 2°C
Oral drench	Preservative efficacy	Ph. Eur. 5.1.3	Log reduction criteria for multidose oral liquids